Generic placeholder image

Current Rheumatology Reviews

Editor-in-Chief

ISSN (Print): 1573-3971
ISSN (Online): 1875-6360

Suppression of Erosive Arthritis by NF-κB Inhibitors

Author(s): Tetsuo Kubota and Kazuo Umezawa

Volume 7, Issue 4, 2011

Page: [275 - 281] Pages: 7

DOI: 10.2174/157339711798221077

Price: $65

Abstract

Excess activation of NF-kappa B is often involved in inflammation and cancer progression. We have developed a specific NF-kappa B inhibitor dehydroxyepoxyquinomicin (DHMEQ). It binds to the specific cysteine residue of Rel family proteins. DHMEQ inhibited cytokine secretions and osteoclastogenesis in cultured macrophages. It inhibited various animal models of inflammation and cancer. Especially, it inhibited type 2-induced rheumatoid arthritis without any toxicity in mice. It also decreased the number of osteoclasts in the inflammatory tissues. Thus, excess activation of NF-kappa B is essential for rheumatoid arthritis, and DHMEQ is a candidate of new anti-rheumatoid chemotherapeutic agent.

Keywords: NF-kappa B, DHMEQ, macrophage, osteoclast, NFATc1, chemotherapy


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy